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Introduction
Centronuclear myopathy (CNM) is a rare congenital disorder 
of striated muscle. It is characterized pathologically by a high 
frequency of central nuclei in the muscle fibers.1 Mutations 
in the gene encoding myotubularinare responsible for the X-
linked recessive form, better known as myotubular myopathy 
(MTM),2 while those of yhe gene encoding dynamin 2 (DNM2) 
account for 50% of autosomal dominant or sporadic cases of 
CNM.3 Some cases with autosomal recessive inheritance are 
related to mutations in the gene encoding amphiphysin 2 
(BIN1).4 Other genetic causes for CNMs with different clini-
co-pathological patterns have recently been identified,5 al-
though there are still genetically unidentified CNM cases.
X-linked MTM usually presents clinically as severe neona-
tal hypotonia and respiratory failure at birth, while CNM of 
autosomal inheritance is not fatal during the perinatal period 
and exhibits a predominantly later onset and heterogeneous 
phenotypes. Typical forms of DNM2-related CNM usually 
commence in late childhood or early adolescence, and have 
slowly progressive clinical courses.3 However, severe and 
neonatal-onset forms with DNM2 mutations and intermediate 
forms between the two extremes have also been reported, 
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Background and PurposezzCentronuclear myopathy (CNM) is characterized by the presence 
of central nuclei within a large number of muscle fibers. Mutations of the dynamin 2 gene (DNM2) 
are common causes of autosomal dominant or sporadic CNM. The aim of this study was to char-
acterize the clinical and pathological features of CNM relative to the presence of DNM2 mutations.
MethodszzSix patients with clinical and pathological features of CNM were recruited. Detailed 
clinical and pathological findings were analyzed according to the presence of DNM2 mutations.
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preferential involvement of the distal lower limbs, typical nuclear centralization, and radially dis-
tributed sarcoplasmic strands in muscle pathology. In contrast, those without DNM2 mutations 
exhibited rather diffuse muscular involvement, and nuclear internalization and myofibrillar dis-
organization were more pronounced features of their muscle pathology.
ConclusionszzThese findings suggest the presence of specific features in Korean CNM patients. 
A detailed clinical and pathological examination of CNM patients would be helpful for molecu-
lar genetic analyses of this condition. J Clin Neurol 2014;10:24-31
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broadening the clinical spectrum of CNM.6-8 Recent studies 
have shown that CNMs associated with mutations of the gene 
encoding ryanodine receptor 1 or BIN1 exhibit a more severe 
phenotype than those associated with DNM2 mutations, even 
to a similar extent to MTM.4,5 They all show common fea-
tures of progressive skeletal muscle weakness with varying 
degrees of facial muscle involvement, ptosis, and external 
ophthalmoplegia.7 Like other congenital myopathies, the 
muscle pathology of CNM usually displays type 1 fiber atro-
phy/predominance. It may exhibit a radial distribution of sar-
coplasmic strands around central nuclei and nonreactive ar-
eas for oxidative enzymes.7
In the present study, the DNM2 genotype was sequenced 
in six patients with sporadic CNM. Mutations were detected 
in four of these patients. Clinical characteristics that appear to 
be specific to Korean CNM patients are noted and DNM2-mu-
tation-related clinical and pathological features are reported. 
The findings of this study will help toward the development of 
a molecular genetic test for various forms of CNM.
Methods
Patients
Six patients showing clinical features of congenital myopathy 
with histopathological findings of a high frequency of central 
nuclei within muscle fibers were recruited for this study. Writ-
ten informed consent to participate was obtained from each 
patient. This study was approved by the Institutional Review 
Board of Pusan National University Yangsan Hospital.
Mutational analyses of DNM2
Direct sequencing analysis of DNM2 was performed to detect 
genetic mutations. Genomic DNA was extracted from the pa-
tients’ peripheral leukocytes or skeletal muscles. PCR reac-
tions were conducted using standard procedures with 20 pairs 
of primers (available on request) covering 20 exons and the 
exon-intron boundaries of DNM2. Myotonic discharge on 
needle EMG was detected in patient 1, leading to Southern 
blot analysis of the gene encoding dystrophia myotonica pro-
tein kinase (DMPK) to exclude the possibility of myotonic 
dystrophy.
Patient characterization and clinical analysis
Clinical information was obtained from the patients regarding 
the age at CNM onset, affected family members, initial symp-
tom, distribution of muscle weakness, current disability, and 
disease progression. Three of the patients underwent muscle 
computed tomography (CT), and serum creatine kinase (CK) 
was measured in all patients.
Muscle pathology
Routine histochemical staining procedures including hema-
toxylin and eosin, modified Gomori trichrome, nicotinamide 
adenine dinucleotide dehydrogenase-tetrazolium reductase 
(NADH-TR), and adenosine triphosphotase (ATPase) were 
applied to the biopsied muscle specimens. Muscle specimens 
were also prepared for electron microscopy by first fixing them 
with 2% glutaraldehyde in 0.1 M cacodylate buffer. After 
shaking with a mixture of 4% osmium tetroxide, 1.5% lantha-
num nitrate, and 0.2 M s-collidine for 2–3 hours, the samples 
were embedded in epoxy resin. Semithin (1-µm-thick) sec-
tions were cut and then stained with toluidine blue. Ultrathin 
(50-nm-thick) sections were then cut and stained with uranyl 
acetate and lead citrate.
Results
Mutational analyses of DNM2
Direct sequencing of DNM2 yielded four kinds of heterozy-
gous missense mutations in four of the six patients. The E650K 
(c.1948G>A) mutation found in patient 1 is located on the GT-
Pase effector domain.9 Patient 2 harbored an R522H (c.1565G> 
A) mutation in the N-terminal of the Pleckstrin homology 
(PH) domain.10 Two of the other mutations, R369Q (c.1106G> 
A) in patient 3 and E368K (c.1102G>A) in patient 4, are lo-
cated in the middle domain. No pathogenic DNM2 mutation 
was found in patients 5 and 6.
Clinical analyses
The clinical data from six patients are summarized in Table 1. 
Three of the patients (patients 1, 3, and 4) experienced their 
first symptoms during childhood, while the onset in patient 2 
was in early adolescence. The other two patients (patients 5 
and 6) had motor developmental delay during infancy: patient 
5 achieved independent ambulation at the age of 18 months, 
and patient 6 could stand up around the age of 1 year. None 
of the patients reported perinatal or antenatal complications.
At the first examination, patients 1, 2, and 4 exhibited distal 
limb dominant muscle weakness, while patients 5 and 6 ex-
hibited proximal dominant limb weakness. In patient 3, mus-
cle weakness was evenly distributed between the proximal 
and distal limbs. Neck flexor weakness was noted in five of 
the patients. Facial paresis with incomplete ptosis was ob-
served in patients 1, 4, and 5, and external ophthalmoplegia 
was detected in patients 1, 3, 4, and 5. Achilles tendon con-
tractures were also common, being present in four of the pa-
tients; patient 1 had bilateral Achilles tenorrhaphy at the age 
of 10 years. None of the patients noted jaw muscle contrac-
tures. Patients 3, 4, and 5 exhibited lumbar lordosis, and pa-
tient 6 had severe scoliosis requiring a corrective operation. 
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Respiratory problems were observed in two of the patients. 
Patient 5 displayed a mild restrictive pattern on the pulmo-
nary function test. Patient 6 began to suffer from dyspnea at 
the age of 18 years; she was found to have a vital capacity of 
32% of normal, and is now dependent on a noninvasive ven-
tilator.
Three of the patients underwent muscle CT (patients 1, 4, 
and 6). In patients 1 and 4, the gastrocnemius and soleus 
muscles were the most preferentially involved (arrows in Fig. 
1B and E), while in patient 1 the biceps femoris and rectus 
femoris were also involved (arrowheads in Fig. 1A), and in 
patient 4 the biceps femoris and vasti muscles were also in-
volved (arrowheads in Fig. 1D). Patient 6 revealed no prefer-
ential involvement of muscles, and exhibited diffuse muscle 
atrophy in both the anterior and posterior compartments of the 
lower legs and thigh muscles (Fig. 1G, H, and I). The muscles 
in the hip girdles were involved in patients 1 and 6, whereas 
they were relatively spared in patient 4 (Fig. 1C, F, and I).
Serum CK levels were either normal or mildly elevated 
(23–454 IU/L) in all patients. Electrophysiological studies 
revealed normal nerve conduction status and myopathic mo-
tor unit potentials in all patients. Myotonic discharge was ob-
served in patient 1; genetic testing for DMPK revealed a re-
peat sequence of the normal range in this patient.
At a follow-up, patients 4 and 6 are not able to ambulate 
independently, while the other four patients remain ambulant. 
Of these four, patient 6 has been unable to stand up spontane-
ously since middle school, and had been using a wheelchair 
since the age of 20 years.
Muscle pathology
Muscle biopsies from all six patients were reviewed (Figs. 2 
and 3). Nuclear misplacement (mostly nuclear centralization) 
was detected in almost all muscle fibers (99%) from patients 
Table 1. Clinical data of 4 patients
With DNM2 mutations Without DNM2 mutations
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Sex/Age F/35 M/22 F/49 F/34 F/6 F/19








Family history Not available (-) (-) (-) (-) (-)
Motor power 
 Neck 4 5 4 3 3 4
 Proximal 4+ 5 4 2–3 4 2–3
 Distal 4 3–4+ 4 2–4 5 4–5
Facial involvement (+) (-) (-) (+) (+) (-)
Ptosis (+) (-) (-) (+) (+) (-)
Ophthalmoplegia (+) (-) (+) (+) (+) (-)
DTR Absent Absent Preserved Absent Absent Absent
Achilles contracture (+) (+) (-) (-) (+) (+)
Lumbar lordosis (-) (-) (+) (+) (+) Scoliosis
Serum CK (IU/L) 270 454 27 60 23 30













Muscle CT GC>TA, 
post. thigh






















CK: creatine kinase, DMN2: dynamin 2 gene, DTR: deep tendon reflex, EMG: electromyography, GC: gastrocnemius, MUP: motor unit 
potential, NCS: nerve conduction study, ND: not done, TA: tibialis anterior.
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1, 2, and 4, and in around 80% of muscle fibers from patient 3 
(Fig. 1A and D). Nuclear chains were demonstrated in longi-
tudinal sections (Fig. 1B). NADH-TR staining revealed a ra-
dial arrangement of sarcoplasmic strands in patients 1, 3, and 
4, and central areas containing nuclei were not reactive for 










Fig. 1. Muscle CT scans of patients 1, 
4, and 6. In patient 1, the rectus femoris 
and biceps femoris were mildly atro-
phied (arrowheads, A), while the poste-
rior compartment of the lower legs was 
the most preferentially involved (arrows, 
B). The hip girdle muscles in patient 1 
were somehow affected (C). In patient 
4, muscles in the posterior lower legs 
were more prominently atrophied (ar-
rows, E) and the biceps femoris and 
vasti muscles were also affected (ar-
rowheads, D); however, the hip girdle 
muscles were relatively spared (F). In 
patient 6, the muscles in the thighs (G), 
lower legs (H), and hip girdle (I) were 
evenly atrophied.
Fig. 2. Muscle pathology in patients 1 and 4. In patient 1, most of the nuclei were placed in the center of the muscle fibers in hematoxylin 
and eosin (H&E) staining (A), a nuclear chain was highlighted in a longitudinal H&E-stained section (B), and sarcoplasmic strands were ra-
dially arranged in nicotinamide adenine dinucleotide dehydrogenase-tetrazolium reductase (NADH-TR) staining (C). In patient 4, most of 
the nuclei were centrally placed in H&E staining (D), and radial arrangement of the sarcoplasmic strands and nonreactive regions for the 
enzyme were demonstrated in NADH-TR staining (E). Accumulation of stain and peripheral halos were observed in some fibers (arrows in 
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cumulation of stains and peripheral halos (arrows in Fig. 2E). 
Myofibrils were absent around the nucleus, and radially ar-
ranged sarcoplasmic strands around the central nucleus were 
also found in electron microscopy (Fig. 2F).
Patients 5 and 6 had nuclear misplacement, both central-
ization and internalization, in 31.6% and 40.6% of muscle fi-
bers, respectively. In patient 5, nuclear centralization and in-
ternalization were found in 18.7% (range, 15.7–22.1%) and 
25.8% (range, 19.6–32.5%) of muscle fibers, respectively. In 
patient 6, nuclear centralization and internalization were ob-
served in 13.1% (range, 11.1–17.1%) and 17.6% (range, 12.9– 
20.5%) of muscle fibers, respectively. Misplaced nuclei were 
contained mostly in small type 1 fibers in patient 5 (Fig. 3A), 
and frequently appeared multiply within a single muscle fiber 
in patients 5 and 6 (Fig. 3A and D). The areas containing cen-
tral nuclei were nonreactive for NADH-TR in some fibers 
from patient 5 (Fig. 3B), but most of the fibers in patient 6 had 
no abnormal NADH-TR staining patterns (Fig. 3E). Myofi-
brillar ATPase staining revealed that type 1 fibers were pre-
dominant and atrophied (Fig. 3C and F), even mimicking the 
pattern of congenital fiber type disproportion in patient 5 
(Fig. 3C). The presence of a central nucleus was not associat-
ed with radial arrangement of sarcoplasmic strands (Fig. 3G), 
but small areas of myofibrillar disorganization were found 
(Fig. 3H) in patient 6 in electron microscopy.
All of the muscle pathologies were free of dystrophic chang-
es. However, the amount of interstitial connective tissue was 
significantly increased in all patients.
Fig. 3. Muscle pathology in patients 5 and 6. In patient 5, nuclear centralization and internalization were mostly found in the small fibers in 
H&E staining (A), and nonreactive regions for NADH-TR were observed in some fibers (B). With myofibrillar ATPase stain (pH 10.7), type I 
fiber atrophy and predominance was noted in patient 5, mimicking the pattern of congenital fiber type disproportion (C). In patient 6, nuclear 
centralization and internalization were noted, and multiple internal nuclei appeared frequently in H&E staining (D), an abnormal pattern of 
staining was absent in NADH-TR staining (E), and type 1 fiber predominance was noted in ATPase staining (F; pH 10.7). Radial arrange-
ment of sarcoplasmic strands was not observed around a central nucleus (G), but small areas of myofibrillar disorganization were detected 
(H) in muscle biopsy tissue from patient 6 in electron microscopy. NADH-TR: nicotinamide adenine dinucleotide dehydrogenase- tetrazoli-
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Discussion
This study recruited six patients with clinical features of con-
genital myopathy and high frequency of central nuclei within 
muscle fibers as a main pathological feature. Gene sequenc-
ing revealed that four of these patients harbored four differ-
ent types of DNM2 mutations. This is consistent with previ-
ous results showing that DNM2 is responsible for more than 
50% of autosomal dominant or sporadic cases of CNM.11 The 
mutations of this study were scattered over three different do-
mains, as described previously for CNM cases of mild phe-
notypes, although the E368K mutation has occasionally been 
reported in association with infantile or neonatal onset. Two 
of the mutations in the middle domain, E368K and R369Q, 
are among the most common DNM2 mutations associated 
with CNM.11 An initial study about DNM2 mutations found 
that a mild CNM phenotype was associated with mutations 
in the middle domain.3 However, many mutations in the other 
domains have also been described in patients with mild CNM, 
indicating that there is no correlation between phenotypes and 
specific domains.10 DNM2 is also responsible for autosomal 
dominant Charcot-Marie-Tooth disease (CMT), and several 
mutations in the PH domain have been described in that dis-
ease. Some DNM2-related CNM cases exhibit slowed motor 
conduction velocities on nerve conduction studies, suggesting 
an overlap between these two diseases. However, none of the 
patients in the present study with DNM2 mutations had marked 
nerve conduction abnormalities, which suggests that periph-
eral nerve involvement is not consistently present in DNM2-
related CNM patients, even when mutations are present in the 
PH domain. Supporting this notion, one recent study showed 
that different functional defects caused by each of the CNM- 
and CMT-related DNM2 mutations are mediated in the de-
velopment of the diseases.12
The clinical presentation differed between patients with 
and without DNM2 mutations in this study. Those with DNM2 
mutations suffered from weakness in the lower legs, whereas 
those without mutations complained of proximal lower limb 
weakness at the first examination. This pattern was clearly re-
produced on muscle CT scans. In patients 1 and 4, the poste-
rior lower leg muscles were the most prominently atrophied. 
However, no preferential muscular involvement was observed 
in patient 6. This finding is compatible with a previous report 
of the posterior compartment of the distal lower legs being 
the most prominent muscular involvement in DNM2-related 
CNM.13 However, the thigh and pelvic muscle involvements 
in DNM2-related CNM appear to vary between studies. The 
present study demonstrated additional involvement of the bi-
ceps femoris and rectus femoris muscles in patient 1 and the 
biceps femoris and vasti muscles in patient 4; in contrast, these 
muscles were comparatively preserved in a previous study.14 
Recognizing these patterns of muscle involvement will help 
to differentiate between congenital myopathies of different 
genetic causes, with increasing use of muscle imaging as an 
initial evaluation tool.
Respiration difficulty occurred only in the patients without 
DNM2 mutations, who already presented with respiratory re-
striction at the first examination, and ultimately required re-
spiratory rehabilitation or ventilator support during follow-up. 
At the last follow-up, none of the patients with DNM2 muta-
tions complained of respiratory problems. In fact, many of 
the published reports on CNM have focused on respiratory 
distress in DNM2-related CNM patients. Recent results of an 
Italian and German CNM cohort show that all patients with 
DNM2 mutations had a restrictive ventilatory defect with 
varying degrees of severity.15,16 However, in the present study, 
respiratory restriction was observed exclusively in patients 
without DNM2 mutations; this may therefore be a Korean-
specific CNM characteristic.
Patients with DNM2 mutations experienced onset on child-
hood or early adolescence, while in those without DNM2 mu-
tations the disease began during infancy with motor develop-
mental delay. However, the present results cannot show 
categorically that the clinical courses of CNM are determined 
by the presence of DNM2 mutations, since clinical courses 
vary even among patients with DNM2-related CNM. Neonatal 
onset and severe courses of CNM were reported with DNM2 
mutations in the C-terminal of the PH domain.14
Regardless of DNM2 mutations, all six CNM patients pre-
sented slowly progressive limb weakness with or without fa-
cial involvement and ophthalmoplegia. Facial paresis and 
ptosis (3/6, 50%), external ophthalmoplegia (4/6, 66.7%), and 
neck flexor weakness (5/6, 83.3%) were common, and thus 
might be dominant features in CNM. It is especially notable 
that patient 2 harbored the R522H mutation and did not pres-
ent with external ophthalmoplegia, in agreement with several 
other reports of CNM patients with R522H not displaying 
ophthalmoplegia.10 Joint contractures and scoliosis/lumbar 
lordosis were also common from earlier stages of the disease. 
Accordingly, appropriate physical or surgical corrections can 
improve motor status and help prevent further complications 
in CNM patients. However, jaw muscle contractures were to-
tally absent in the present series, although according to other 
reports it appears to be both common and pronounced, in 
particular with the E368K mutation.15
It is notable that the presence of DNM2 mutations was as-
sociated with distinct pathological findings. Frequent central 
nuclei and type 1 fiber atrophy/predominance were common 
in all patients. However, in DNM2-related cases, 1) nuclear 
centralization was the most frequent characteristic (80–99%) 
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and 2) sarcoplasmic strands were radially distributed around 
the central nuclei. By contrast, in patients without DNM2 mu-
tations, 1) both nuclear internalization and nuclear centraliza-
tion were marked, 2) misplaced nuclei were less frequently 
observed (31.6–40%), and 3) sarcoplasmic strands were not 
radially arranged. Electron microscopic observation revealed 
small areas of myofibrillar disorganization as an additional 
finding in the absence of DNM2 mutations. However, reac-
tivity for oxidative enzymes in the center of the muscle fibers 
was variable, regardless of the presence of DNM2 mutations. 
These findings are consistent with previous reports on the 
pathological features of CNM. A recent study of CNM found 
that its pathological manifestation vary with the genetic 
causes.17 Variable pathological features, such as nuclear inter-
nalization, necklace fibers,18 and myofibrillar disorganiza-
tion,5 suggest other genetic causes of CNM, while radial sar-
coplasmic strands are always typical of DNM2-related cases. 
Another Japanese report also underlined homogeneous path-
ological features in DNM2-related CNM.19 Considering our 
results and those of previous studies, exclusive centralization 
of the nuclei and radial arrangement of sarcoplasmic strands 
may be consistent pathologic markers of DNM2 mutations in 
CNM patients.
In conclusion, to our knowledge this is the first reported 
study of Korean CNM patients, and it has shown that DNM2 
mutations may be one of the more frequent genetic causes of 
sporadic CNM in Korea. Clinical presentations revealed the 
presence of several characteristics in Korean CNM patients, 
and demonstrated some differences between patients with 
and without DNM2 mutations. Muscle imaging findings sup-
port the notion that specific muscular involvement of distal 
lower limbs may help distinguish DNM2-related CNM from 
other genetic causes. It is notable that respiratory restriction 
was not observed in the present cohort of DNM2-related CNM 
patients, and that jaw contractures appear to be uncommon 
in Korean CNM patients regardless of the presence of DNM2 
mutations. The pathological features in patients with DNM2 
mutations described herein appear to be consistent with the 
findings of previous studies: nuclear centralization is more 
marked than in those without DNM2 mutations, and the sar-
coplasmic strands are radially arranged. Furthermore, it was 
found that other pathological features, such as myofibrillar 
disorganization, can be present in the absence of DNM2 mu-
tations. Although genetic causes can be evaluated in patients 
without DNM2 mutations, the findings of this study imply 
that careful examination for clinical and pathological findings 
can guide molecular genetics analyses of CNM.
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